- Home
- ARQT vs MYRG Comparison
ARQT vs MYRG Comparison
Compare ARQT & MYRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- MYRG
- Stock Information
- Founded
- ARQT 2016
- MYRG 1891
- Country
- ARQT United States
- MYRG United States
- Employees
- ARQT N/A
- MYRG N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- MYRG Water Sewer Pipeline Comm & Power Line Construction
- Sector
- ARQT Health Care
- MYRG Industrials
- Exchange
- ARQT Nasdaq
- MYRG Nasdaq
- Market Cap
- ARQT 2.0B
- MYRG 2.3B
- IPO Year
- ARQT 2020
- MYRG N/A
- Fundamental
- Price
- ARQT $13.80
- MYRG $112.77
- Analyst Decision
- ARQT Strong Buy
- MYRG Strong Buy
- Analyst Count
- ARQT 6
- MYRG 6
- Target Price
- ARQT $18.80
- MYRG $147.83
- AVG Volume (30 Days)
- ARQT 2.6M
- MYRG 202.2K
- Earning Date
- ARQT 05-13-2025
- MYRG 04-30-2025
- Dividend Yield
- ARQT N/A
- MYRG N/A
- EPS Growth
- ARQT N/A
- MYRG N/A
- EPS
- ARQT N/A
- MYRG 1.83
- Revenue
- ARQT $196,542,000.00
- MYRG $3,362,290,000.00
- Revenue This Year
- ARQT $60.21
- MYRG $5.11
- Revenue Next Year
- ARQT $40.21
- MYRG $5.94
- P/E Ratio
- ARQT N/A
- MYRG $61.84
- Revenue Growth
- ARQT 229.74
- MYRG N/A
- 52 Week Low
- ARQT $6.99
- MYRG $86.60
- 52 Week High
- ARQT $17.75
- MYRG $171.10
- Technical
- Relative Strength Index (RSI)
- ARQT 46.44
- MYRG 45.88
- Support Level
- ARQT $12.51
- MYRG $108.51
- Resistance Level
- ARQT $13.67
- MYRG $115.67
- Average True Range (ATR)
- ARQT 1.43
- MYRG 7.42
- MACD
- ARQT -0.27
- MYRG 0.67
- Stochastic Oscillator
- ARQT 34.83
- MYRG 65.25
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About MYRG MYR Group Inc.
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution network and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.